{"id":"NCT00124020","sponsor":"Cumberland Pharmaceuticals","briefTitle":"Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus","officialTitle":"A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-01","primaryCompletion":"2007-05","completion":"2007-05","firstPosted":"2005-07-26","resultsPosted":"2010-02-01","lastUpdate":"2019-01-16"},"enrollment":771,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Pneumonia"],"interventions":[{"type":"DRUG","name":"Telavancin","otherNames":["TD6424","VIBATIV"]},{"type":"DRUG","name":"Vancomycin","otherNames":[]}],"arms":[{"label":"Telavancin","type":"EXPERIMENTAL"},{"label":"Vancomycin","type":"ACTIVE_COMPARATOR"}],"summary":"Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.","primaryOutcome":{"measure":"Clinical Response","timeFrame":"7-14 days following end of antibiotic treatment","effectByArm":[{"arm":"Telavancin","deltaMin":227,"sd":null},{"arm":"Vancomycin","deltaMin":228,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Israel"]},"refs":{"pmids":["29454592","27718118","24708675"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":107,"n":379},"commonTop":["Diarrhoea","Constipation","Anemia","Hypokalemia","Hypotension"]}}